REGNRegeneron

Pharma & Healthcare · US · Regeneron Pharmaceuticals, Inc.

4 of 6 ratios computed · receipts verified server-side

Idiot Index

out of 100 · 4/6 ratios · FY 2023

The full receipt

Latest published value for each ratio, with the sector median for context and year-over-year change where the prior year is available.

Markup →
How much revenue per dollar of cost.
Not computed: missing input.
Needed but not in this company's XBRL filings: Cost of Goods Sold.
What this company did disclose: Stock Buybacks, CEO Total Compensation, Total Employee Count, Median Employee Compensation, Net Income, Operating Expenses, R&D Expense, Revenue
Operational Markup →
Revenue per dollar of cost + operating expenses. The multiplier after legitimate operations.
Not computed: missing input.
Needed but not in this company's XBRL filings: Cost of Goods Sold.
What this company did disclose: Stock Buybacks, CEO Total Compensation, Total Employee Count, Median Employee Compensation, Net Income, Operating Expenses, R&D Expense, Revenue
Labor Share →
How much of every revenue dollar reaches workers.
0.1804of revenue → workersapprox.verified
18¢ of every $1 of revenue reaches workers
Sector median: 0.1761Median range for extraction in sector
FY 2023v1.0.0
Executive Extraction →
How many times a CEO out-earns the median employee.
49.35× CEO / median workerverified
CEO earns 49× the median worker
Sector median: 263.0Bottom 4% for extraction in sector
FY 2023v1.0.0
Shareholder Extraction →
Dollars sent to shareholders for every dollar invested in R&D.
0.5753× buybacks+dividends / R&Dverified
$0.58 to shareholders per $1 in R&D — net reinvesting
Sector median: 0.7492Median range for extraction in sector
FY 2023v1.0.0
Capital Extraction →
How much of net profit goes to shareholders rather than back into the business.
0.2038× buybacks+dividends / net incomeverified
20% of net profit returned to shareholders, 80% reinvested
Sector median: 0.5294Bottom 24% for extraction in sector
FY 2023v1.0.0